Clinical Curative Effect Observation of Bumetanide on Elderly Type 2 Diabetic Patients with Middle and Advanced Stages Nephropathy
- VernacularTitle:布美他尼治疗老年2型糖尿病中晚期肾病的临床疗效观察
- Author:
Wenwen MAO
;
Zhenglei SHEN
;
Huifang LI
;
Weimeng TIAN
;
Guoqiang CHEN
- Publication Type:Journal Article
- Keywords:
Bumetanide;
Diabetic nephropathy;
Transferrin;
Urine microalbumin
- From:
Journal of Kunming Medical University
2014;(1):76-79
- CountryChina
- Language:Chinese
-
Abstract:
Objective The purpose of this study was to observe the effects of bumetanide on elderly type 2 diabetic patients with middle and advanced stages nephropathy. Methods Forty cases with diabetic nephropathy (DN) were divided into two groups:control group (20 cases) and treatment group (20 cases) . The control group accepted furosemide (20 mg, once a day) and the bumetanide was orally administrated at the dose of 1.0 mg, twice a day to the treatment group for 3 months. The assessment of transferrin (TRF) and urine microalbumin (UALB) was performed at the time points at the end of 1, 4, 8, 12 weeks after treatment. Results (1) The levels of BUN, SCr and UA after treatment were lower than before treatment, but there were no significant differences. (2) In the treatment group, the levels of TRF and UALB have decreased after treatment for 1 week, with no statistically significant. But at the end of 4, 8 and 12 weeks,the differences were statistically significant ( <0.05) . Especially, during the three months follow-up,the levels of TRF and UALB at 12 weeks have decreased obviously. Conclusion The therapeutic effect of bumetanide on DN might be better than that of furosemide.
